Trial Tests Anti‑Snoring Device as Sleep Apnoea Treatment

*TL;DR A randomized controlled trial of a neck‑mounted anti‑snoring device is underway, aiming to reduce sleep apnoea severity for millions of sufferers.*

Context Sleep apnoea affects an estimated 1 in 5 adults in the UK, causing fragmented sleep, daytime fatigue and heightened cardiovascular risk. Current treatments range from continuous‑positive‑airway pressure (CPAP) machines to oral appliances, but adherence remains low.

Key Facts - Researchers have launched a double‑blind randomized controlled trial (RCT) enrolling 240 participants diagnosed with moderate obstructive sleep apnoea. Participants receive either the anti‑snoring device, a soft boomerang‑shaped band worn around the neck, or a sham device that looks identical but provides no therapeutic pressure. - The primary endpoint is the change in the apnoea‑hypopnea index (AHI), the number of breathing interruptions per hour, measured after eight weeks of nightly use. Secondary outcomes include sleep quality scores, daytime sleepiness, and blood pressure. - Preliminary safety data show no serious adverse events; minor skin irritation occurred in 4 % of users. - The trial is part of a broader health‑tech push, highlighted by two entrepreneurs: one who survived a heart attack at 44 and now develops tools to shorten hospital recovery, and another who lost a family member to breast cancer and creates education platforms for early detection in Pakistan.

What It Means If the device demonstrates a statistically significant reduction in AHI compared to the sham, it could become the first over‑the‑counter option that addresses snoring and apnoea without the cost or complexity of CPAP. Because the device is non‑invasive and easy to wear, it may improve adherence among patients who abandon existing therapies.

For consumers, the trial suggests a near‑future alternative that can be tried at home, with the potential to lower blood pressure and improve daytime alertness. Clinicians should watch for the trial’s final results before recommending the device as a standard treatment.

Looking ahead The study’s outcome will be published later this year; its findings will determine whether the anti‑snoring device moves from experimental to mainstream therapy for sleep apnoea.